华兰生物
(002007)
| 流通市值：235.51亿 | | | 总市值：273.57亿 |
| 流通股本：15.73亿 | | | 总股本：18.27亿 |
| 报告期 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 774,812,955.1 | 1,687,492,464.31 | 1,160,346,064.35 | 1,102,190,831.95 |
| 交易性金融资产 | 2,623,447,951.95 | 2,388,803,071.41 | 1,767,147,237.15 | 2,546,993,797.38 |
| 应收票据及应收账款 | 1,799,143,322.59 | 1,959,553,683.15 | 1,581,262,799.13 | 1,870,813,379.2 |
| 应收账款 | 1,799,143,322.59 | 1,959,553,683.15 | 1,581,262,799.13 | 1,870,813,379.2 |
| 应收款项融资 | 278,636,148.78 | 257,354,292.89 | 145,854,393.56 | 197,154,765.85 |
| 预付款项 | 28,159,046.81 | 56,405,538.38 | 45,443,452.17 | 91,106,230.94 |
| 其他应收款合计 | 5,407,641.79 | 16,775,755.4 | 15,072,120.24 | 19,375,503.95 |
| 存货 | 2,288,507,710.6 | 2,288,322,465.5 | 2,303,490,511.79 | 2,231,831,545.8 |
| 一年内到期的非流动资产 | 904,682,489.76 | 1,338,406,006.94 | 2,261,027,215.27 | 2,384,265,798.6 |
| 其他流动资产 | 156,504,761.82 | 55,601,612.03 | 56,420,440.24 | 106,091,894.22 |
| 流动资产合计 | 8,859,302,029.2 | 10,048,714,890.01 | 9,336,064,233.9 | 10,549,823,747.89 |
| 非流动资产: | | | | |
| 长期股权投资 | 118,027,845.96 | 35,423,753.6 | - | - |
| 固定资产 | 2,329,454,312.6 | 2,336,679,790.46 | 2,382,511,896.99 | 2,404,631,459.2 |
| 在建工程 | 643,371,330.9 | 617,656,303.59 | 584,891,844.39 | 563,982,791.49 |
| 生产性生物资产 | 1,030,354.18 | 1,398,553.37 | 523,090.71 | 531,685.26 |
| 使用权资产 | 8,546,086.09 | 8,689,381.35 | 8,832,676.59 | 8,975,971.83 |
| 无形资产 | 314,131,612.38 | 318,944,426.7 | 313,548,524.8 | 316,138,918.75 |
| 开发支出 | 27,923,495 | 27,867,304 | 27,864,900.22 | 27,864,900.22 |
| 长期待摊费用 | 27,386,238.12 | 28,027,884.06 | 28,949,829.45 | 30,408,318.72 |
| 递延所得税资产 | 196,851,399.69 | 225,987,238.56 | 243,947,882.17 | 224,119,716.13 |
| 其他非流动资产 | 2,736,242,009.64 | 2,617,980,081.86 | 2,608,305,521.29 | 2,512,443,441.86 |
| 非流动资产合计 | 6,402,964,684.56 | 6,218,654,717.55 | 6,199,376,166.61 | 6,089,097,203.46 |
| 资产总计 | 15,262,266,713.76 | 16,267,369,607.56 | 15,535,440,400.51 | 16,638,920,951.35 |
| 流动负债: | | | | |
| 短期借款 | 447,000,000 | 447,000,000 | 280,000,000 | 1,079,380,000 |
| 应付票据及应付账款 | 196,262,447.99 | 210,551,260.22 | 206,262,397.24 | 230,809,400.13 |
| 其中：应付票据 | 8,485,471.65 | 20,490,973.73 | 12,005,502.08 | - |
| 应付账款 | 187,776,976.34 | 190,060,286.49 | 194,256,895.16 | 230,809,400.13 |
| 合同负债 | 10,210,096.09 | 10,158,422.92 | 21,687,891.8 | 16,962,615.42 |
| 应付职工薪酬 | 204,449.97 | 422,073.84 | 112,608.82 | 477,374.46 |
| 应交税费 | 39,475,690.53 | 49,998,579.61 | 36,515,630.06 | 43,023,308.74 |
| 其他应付款合计 | 1,036,470,636.71 | 2,207,222,662.56 | 920,293,938.12 | 931,285,577.35 |
| 应付股利 | 6,751,022.5 | 1,141,394,879.4 | 116,366,935.6 | - |
| 一年内到期的非流动负债 | 387,879.07 | 371,353.82 | 371,353.82 | 371,353.82 |
| 其他流动负债 | 65,297,981.02 | 304,710.14 | 648,434.2 | 66,066,116.37 |
| 流动负债合计 | 1,795,309,181.38 | 2,926,029,063.11 | 1,465,892,254.06 | 2,368,375,746.29 |
| 非流动负债: | | | | |
| 租赁负债 | 8,389,025.19 | 8,310,032.62 | 8,214,514.84 | 8,114,955.67 |
| 递延收益 | 59,459,833.48 | 49,140,368.61 | 50,820,903.74 | 52,501,438.87 |
| 递延所得税负债 | 8,114,399.06 | 34,292,663.54 | 40,208,851.19 | 37,359,105.56 |
| 非流动负债合计 | 75,963,257.73 | 91,743,064.77 | 99,244,269.77 | 97,975,500.1 |
| 负债合计 | 1,871,272,439.11 | 3,017,772,127.88 | 1,565,136,523.83 | 2,466,351,246.39 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,827,456,666 | 1,827,456,666 | 1,827,456,666 | 1,828,780,926 |
| 资本公积 | 1,397,183,641.34 | 1,424,425,525.81 | 1,420,562,053.53 | 1,430,209,795.99 |
| 减:库存股 | 17,948,737.2 | 17,948,737.2 | 17,948,737.2 | 32,723,064.6 |
| 盈余公积 | 913,736,729.39 | 897,821,103.29 | 897,821,103.29 | 897,821,103.29 |
| 未分配利润 | 7,380,177,249.2 | 7,240,115,231.79 | 7,885,280,035.22 | 8,048,047,860.37 |
| 归属于母公司股东权益合计 | 11,500,605,548.73 | 11,371,869,789.69 | 12,013,171,120.84 | 12,172,136,621.05 |
| 少数股东权益 | 1,890,388,725.92 | 1,877,727,689.99 | 1,957,132,755.84 | 2,000,433,083.91 |
| 股东权益合计 | 13,390,994,274.65 | 13,249,597,479.68 | 13,970,303,876.68 | 14,172,569,704.96 |
| 负债和股东权益合计 | 15,262,266,713.76 | 16,267,369,607.56 | 15,535,440,400.51 | 16,638,920,951.35 |
| 公告日期 | 2026-03-28 | 2025-10-30 | 2025-08-28 | 2025-04-28 |
| 审计意见(境内) | 标准无保留意见 | | | |